Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

115 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-24

Study Completion Date

2025-08-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with prostate cancer. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using small, high doses of radiation over several days and may cause less damage to normal tissue. This treatment schedule allows for a higher dose of radiation to be administered over a shorter overall treatment period in comparison to standard radiation therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prostate Boost Irradiation With Stereotactic Body RT (SBRT)

NCT03380806

Prostate Cancer

UNKNOWN PHASE2

MRI Guided SBRT for Localized Prostate Cancer

NCT03778112

Prostate Cancer

ACTIVE_NOT_RECRUITING NA

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744

Prostate Cancer Prostatic Neoplasm

COMPLETED PHASE1

Single Arm Trial of Preoperative Stereotactic Body Radiation Therapy (SBRT) for T3a or Gleason Grade Group 4 Prostate Cancer

NCT03748719

Prostate Cancer

WITHDRAWN NA

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

NCT02446366

Stage II Prostate Adenocarcinoma Stage IIB Prostate Cancer Stage III Prostate Adenocarcinoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To evaluate the incidence of genitourinary (GU) and gastrointestinal (GI) acute and late toxicity for patients treated with prostate stereotactic body radiotherapy (SBRT) with simultaneous integrative boost, urethral ring sparing, and enhanced prostate localization (magnetic resonance imaging \[MRI\\-computed tomography \[CT\] fusion).

II. To also evaluate the incidence of GU and GI acute and late toxicity for patients treated with prostate stereotactic body radiotherapy (SBRT) with a more conventional and uniformly delivered dose of 7.25 Gy/fraction to the prostate.

III. Disease-free survival: disease-free failure events include local progression, distant progression, biochemical failure as defined by the Radiation Therapy Oncology Group (RTOG) Phoenix definition, and death from any cause.

SECONDARY OBJECTIVES:

I. Evaluate patient quality of life (QOL) using the Expanded Prostate Cancer Index Composite 26 (EPIC-26) for evaluation of the QOL for up to 3 years after the completion of SBRT.

OUTLINE: Participants are assigned to 1 of 2 treatment arms. Participants unable to undergo MRI, whose MRI proves technically inadequate for delineating needed anatomic structures, or who decline to enroll on Arm A are assigned to Arm B.

ARM A: (n = 120) Participants undergo 5 fractions of moderate dose SBRT with simultaneous integrated boost (SIB) every other day for 10 days following urethral-sparing IMRT planning.

ARM B: (n = 40) Participants undergo 5 fractions of uniform dose SBRT every other day for 10 days following undergo urethral-sparing IMRT planning.

After completion of study treatment, patients are followed up at 4-8 weeks, at 4, 8, and 12 months, every 4 months for 1 year, every 6 months for 3 years, and then every 12 months thereafter.

Per protocol amendment in December 2023, the follow up time period for data collection will change to 3 years after the last participant completed treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage I Prostate Adenocarcinoma Stage II Prostate Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A (moderate dose SBRT with SIB)

Patients undergo 5 fractions of moderate dose SBRT with SIB every other day for 10 days following urethral-sparing IMRT planning.

SBRT: 8.0Gy escalated dose

Group Type EXPERIMENTAL

Radiation Therapy Treatment Planning and Simulation

Intervention Type RADIATION

Undergo urethral-sparing IMRT planning

SBRT

Intervention Type RADIATION

Undergo moderate dose SBRT with SIB

Arm B (uniform dose SBRT)

Patients undergo 5 fractions of uniform dose SBRT every other day for 10 days following urethral-sparing IMRT planning.

SBRT: 7.5Gy conventional dose

Group Type ACTIVE_COMPARATOR

Radiation Therapy Treatment Planning and Simulation

Intervention Type RADIATION

Undergo urethral-sparing IMRT planning

SBRT

Intervention Type RADIATION

Undergo uniform dose SBRT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radiation Therapy Treatment Planning and Simulation

Undergo urethral-sparing IMRT planning

Intervention Type RADIATION

SBRT

Undergo moderate dose SBRT with SIB

Intervention Type RADIATION

SBRT

Undergo uniform dose SBRT

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Radiation Therapy Treatment Planning/Simulation Stereotactic Body Radiation Therapy Stereotactic Body Radiation Therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of adenocarcinoma of the prostate and most recent biopsy within 180 days of study enrollment
* History/physical examination with digital rectal examination of the prostate within 90 days prior to study enrollment
* Gleason score =\< 7, no tertiary pattern \>= 5
* Clinical stage =\< T2b (American Joint Committee on Cancer \[AJCC\] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 disease
* Clinical stage N0, M0
* Most recent prostate specific antigen (PSA) within 60 days of enrollment
* Maximum PSA =\< 20 ng/ml (not within 20 days after biopsy)
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* American Urological Association (AUA) =\< 18 with or without medical management
* Up to a total of year of androgen deprivation allowed.
* Participant signs study specific informed consent prior to study enrollment

Exclusion Criteria

* FOR ARM A: Inability to obtain a planning MRI or a planning MRI of sufficient quality to allow identification of the peripheral zone and urethra, or inability to adequately fuse the MRI to the planning CT scan
* FOR BOTH ARM A AND ARM B:
* Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years; (for example, carcinoma in situ of the bladder or oral cavity is permissible)
* Prosthetic implants in the pelvic region that the investigator feels will impede treatment, planning, or delivery (e.g., an artificial hip)
* =\< 3 months from a transurethral resection of the prostate (TURP) procedure
* Significant urinary obstruction (i.e. AUA symptom score \> 18)
* Previous pelvic irradiation, prostate brachytherapy
* Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
* Severe, active comorbidity, defined as follows:

* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
* Crohn's disease or ulcerative colitis
* Scleroderma

Eligible Sex

MALE

Accepts Healthy Volunteers

No